Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in adolescents with heterozygous familial hypercholesterolemia
NCT04652726Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Primary completion
- Nov 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 26
01
Overview
A Phase 3 trial of inclisiran in heterozygous familial hypercholesterolemia (HeFH), sponsored by Novartis. Started Jan 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT04652726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652726.